Response Oncology Stock Net Asset
Response Oncology fundamentals help investors to digest information that contributes to Response Oncology's financial success or failures. It also enables traders to predict the movement of Response Stock. The fundamental analysis module provides a way to measure Response Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Response Oncology stock.
Response |
Response Oncology Company Net Asset Analysis
Response Oncology's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Response Oncology Net Asset | 28.9 M |
Most of Response Oncology's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Response Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Response Oncology has a Net Asset of 28.9 M. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Response Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Response Oncology's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Response Oncology could also be used in its relative valuation, which is a method of valuing Response Oncology by comparing valuation metrics of similar companies.Response Oncology is currently under evaluation in net asset category among its peers.
Response Fundamentals
| Return On Equity | -7.24 | |||
| Return On Asset | -0.0153 | |||
| Profit Margin | (0.47) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 16.62 M | |||
| Shares Outstanding | 12.18 M | |||
| Revenue | 118.08 M | |||
| Gross Profit | 28.17 M | |||
| EBITDA | 1.32 M | |||
| Net Income | (51.39 M) | |||
| Cash And Equivalents | 9.01 M | |||
| Cash Per Share | 0.74 X | |||
| Total Debt | 26.45 M | |||
| Current Ratio | 13.35 X | |||
| Book Value Per Share | (1.54) X | |||
| Cash Flow From Operations | 9.1 M | |||
| Earnings Per Share | (4.16) X | |||
| Number Of Employees | 10 | |||
| Beta | -19.24 | |||
| Market Capitalization | 12 | |||
| Total Asset | 28.9 M | |||
| Retained Earnings | (120.16 M) | |||
| Working Capital | 34.72 M | |||
| Current Asset | 37.25 M | |||
| Current Liabilities | 2.54 M | |||
| Z Score | -0.15 | |||
| Net Asset | 28.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |